{"generic":"Febuxostat","drugs":["Febuxostat","Uloric"],"mono":{"0":{"id":"jx1fs0","title":"Generic Names","mono":"Febuxostat"},"1":{"id":"jx1fs1","title":"Dosing and Indications","sub":[{"id":"jx1fs1b4","title":"Adult Dosing","mono":"<ul><li><b>Gout - Hyperuricemia:<\/b> 40 mg ORALLY once daily; may be increased to 80 mg ORALLY once daily if serum uric acid levels of less than 6 mg\/dL are not achieved after 2 weeks<\/li><li><b>Gout - Hyperuricemia:<\/b> gout flare prophylaxis with an NSAID or colchicine is recommended when initiating therapy<\/li><\/ul>"},{"id":"jx1fs1b5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"jx1fs1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> mild to moderate (CrCl, 30 to 89 mL\/min), no dosage adjustment necessary<\/li><li><b>hepatic impairment:<\/b> mild to moderate (Child-Pugh class A or B), no dosage adjustment necessary<\/li><li><b>geriatric patients:<\/b> no dosage adjustment necessary<\/li><\/ul>"},{"id":"jx1fs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Gout - Hyperuricemia<br\/>"}]},"3":{"id":"jx1fs3","title":"Contraindications\/Warnings","sub":[{"id":"jx1fs3b9","title":"Contraindications","mono":"concomitant use of azathioprine or mercaptopurine <br\/>"},{"id":"jx1fs3b10","title":"Precautions","mono":"<ul><li>cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions (MI), and non-fatal strokes) have been reported; monitoring for signs and symptoms of MI and stroke is recommended<\/li><li>conditions which greatly increase urate formation rate (eg, malignant disease and treatment, Lesch-Nyhan syndrome); use is not recommended<\/li><li>gout flare may occur after initiating treatment; prophylactic coadministration of an NSAID or colchicine is recommended when initiating febuxostat<\/li><li>hepatic impairment, severe (Child-Pugh class C); no data available, exercise caution<\/li><li>liver enzyme elevations have been reported; periodic monitoring is recommended<\/li><li>renal impairment, severe (CrCl less than 30 mL\/min); no data available, exercise caution<\/li><li>report suspected adverse events to Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jx1fs3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jx1fs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jx1fs4","title":"Drug Interactions","sub":{"0":{"id":"jx1fs4b13","title":"Contraindicated","mono":"<ul><li>Azathioprine (theoretical)<\/li><li>Mercaptopurine (theoretical)<\/li><\/ul>"},"2":{"id":"jx1fs4b15","title":"Moderate","mono":"<ul>Theophylline (probable)<\/ul>"}}},"5":{"id":"jx1fs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash (0.5% to 1.6%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (1.1% to 1.3%)<\/li><li><b>Hepatic:<\/b>Liver enzymes abnormal (4.6% to 6.6%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (0.7% to 1.1%), Gout, acute<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Death, Cardiovascular, Myocardial infarction<\/li><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome<\/li><li><b>Hematologic:<\/b>Idiopathic thrombocytopenic purpura (less than 1%), Thromboembolic disorder<\/li><li><b>Hepatic:<\/b>Hepatitis (less than 1%), Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction (less than 1%)<\/li><li><b>Musculoskeletal:<\/b>Rhabdomyolysis<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident (less than 1%), Transient ischemic attack (less than 1%)<\/li><li><b>Renal:<\/b>Renal failure (less than 1%), Tubulointerstitial nephritis<\/li><li><b>Other:<\/b>Angioedema (less than 1%)<\/li><\/ul>"},"6":{"id":"jx1fs6","title":"Drug Name Info","sub":{"0":{"id":"jx1fs6b17","title":"US Trade Names","mono":"Uloric<br\/>"},"2":{"id":"jx1fs6b19","title":"Class","mono":"<ul><li>Antigout<\/li><li>Xanthine Oxidase Inhibitor<\/li><\/ul>"},"3":{"id":"jx1fs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jx1fs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jx1fs7","title":"Mechanism Of Action","mono":"Febuxostat is a xanthine oxidase inhibitor which acts by decreasing serum uric acid.<br\/>"},"8":{"id":"jx1fs8","title":"Pharmacokinetics","sub":[{"id":"jx1fs8b23","title":"Absorption","mono":"<ul><li>Bioavailability: (oral), at least 49%<\/li><li>Effect of food: (oral, 80 mg), Cmax decrease by 49% and AUC decrease by 19%; may be taken without regard to food<\/li><li>Tmax: (oral), 1  to 2.1 hours<\/li><\/ul>"},{"id":"jx1fs8b24","title":"Distribution","mono":"<ul><li>Vd: 47.1  to 50 L<\/li><li>Protein binding: (oral, 40 or 80 mg), 99.2%<\/li><\/ul>"},{"id":"jx1fs8b25","title":"Metabolism","mono":"<ul><li>Hepatic; uridine diphosphate glucuronosyltransferase (UGT) enzymes (eg, UGT1A1, UGT1A3, UGT1A9, UGT2B7) and CYP450 enzymes (eg, CYP1A2, CYP2C8, CYP2C9) and non-CYP450 enzymes<\/li><li>Active metabolites: hydroxy febuxostat metabolites<\/li><\/ul>"},{"id":"jx1fs8b26","title":"Excretion","mono":"<ul><li>Fecal: (oral, 80 mg), 45%, 12% unchanged<\/li><li>Renal: (oral, 80 mg), 49%, 3% unchanged<\/li><li>Total body clearance: 5.6 L\/hr<\/li><\/ul>"},{"id":"jx1fs8b27","title":"Elimination Half Life","mono":"5 to 8 hours <br\/>"}]},"10":{"id":"jx1fs10","title":"Monitoring","mono":"<ul><li>serum uric acid levels; 2 weeks after initiating therapy; target level below 6 mg\/dL<\/li><li>liver function tests; at baseline and repeat during therapy in patients with symptoms of liver failure<\/li><li>signs and symptoms of myocardial infarction and stroke<\/li><\/ul>"},"11":{"id":"jx1fs11","title":"How Supplied","mono":"<b>Uloric<\/b><br\/>Oral Tablet: 40 MG, 80 MG<br\/>"},"12":{"id":"jx1fs12","title":"Toxicology","sub":[{"id":"jx1fs12b31","title":"Clinical Effects","mono":"<b>FEBUXOSTAT<\/b><br\/>USES: Non-purine selective xanthine oxidase inhibitor used for chronic management of hyperuricemia in patients with gout. PHARMACOLOGY: Decreases serum uric acid. EPIDEMIOLOGY: At the time of this review, there were no reports of human overdose. Overdose effects are anticipated to be extension of adverse effects seen at therapeutic doses. OVERDOSE: At the time of this review, there was no overdose information available; extension of adverse effects seen at therapeutic doses should be anticipated. ADVERSE EFFECTS: COMMON: Liver enzyme elevations, headaches, flushing, dizziness, nausea, arthralgia, and rash. An increase in gout flares has been reported following initiation of febuxostat therapy.<br\/>"},{"id":"jx1fs12b32","title":"Treatment","mono":"<b>FEBUXOSTAT<\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: PREHOSPITAL: Consider activated charcoal in patients who are awake and able to maintain their airway. HOSPITAL: Consider activated charcoal after a potentially toxic ingestion and if the patient is able to maintain airway or if airway is protected.<\/li><li>Antidote: None<\/li><li>Monitoring of patient: Monitor hepatic enzymes in symptomatic patients; however,  no specific lab work (CBC, electrolyte, urinalysis) is needed in asymptomatic patients unless otherwise clinically indicated.<\/li><li>Enhanced elimination procedure: Hemodialysis is unlikely to be effective due to high protein binding.<\/li><\/ul>"},{"id":"jx1fs12b33","title":"Range of Toxicity","mono":"<b>FEBUXOSTAT<\/b><br\/>TOXICITY: No dose-limiting toxicities were reported following administration of doses up to 300 mg\/day for 7 days. THERAPEUTIC DOSE: 40 to 80 mg\/day.<br\/>"}]},"13":{"id":"jx1fs13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause nausea, rash, or arthralgia.<\/li><li>Advise patient to report signs\/symptoms of gout flares or elevated liver enzymes.<\/li><li>Patient should report signs\/symptoms of cardiovascular events or a stroke (eg, chest pain, shortness of breath, or neurologic symptoms).<\/li><\/ul>"}}}